



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Mekinist® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)	Provider Information (required)
-------------------------------	---------------------------------

Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

Select the diagnosis below:

Anaplastic thyroid cancer (ATC)

Melanoma

Non-small cell lung cancer (NSCLC)

Other diagnosis: _____ ICD-10 Code(s): _____

Clinical Information:

Is Mekinist prescribed by or in consultation with an oncologist? Yes No

Is this request for continuation of prior Mekinist therapy? Yes No

Has the patient used Mekinist within the past 120 days? Yes No

Will Mekinist be used in combination with Tafinlar (dabrafenib)? Yes No

Select if the cancer has the following mutation type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA), as appropriate for the patient's diagnosis:

BRAF V600E BRAF V600K

For anaplastic thyroid cancer, also answer the following:

Does the patient have locally advanced or metastatic anaplastic thyroid cancer (ATC)? Yes No

Is the cancer treatable with standard locoregional treatment options? Yes No

For melanoma, also answer the following:

Does the patient have unresectable or metastatic melanoma? Yes No

Will Mekinist be used as adjuvant therapy? Yes No

Is there involvement of lymph nodes following complete resection? Yes No

For non-small cell lung cancer (NSCLC), also answer the following:

Does the patient have metastatic non-small cell lung cancer (NSCLC)? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.
 For urgent or expedited requests please call 1-800-711-4555.
 This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Mekinist_CMS_2019Jan-W